Logo

Imara to Discontinue P-IIb (Ardent & Forte) Trial of Tovinontrine (IMR-687) for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Share this
Imara to Discontinue P-IIb (Ardent & Forte) Trial of Tovinontrine (IMR-687) for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Imara to Discontinue P-IIb (Ardent & Forte) Trial of Tovinontrine (IMR-687) for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Shots:

  • The company will stop P-IIb (Ardent & Forte) trial to evaluate tovinontrine (IMR-687) in patients with SCD & beta-thalassemia with an expected plan to discontinue in Q2’22
  • The discontinuation was based on the interim results of (Ardent) trial for SCD which showed no significant difference in median annualized VOC RATE in the high-dose group in the ITT population, 4 (3.6%) patients discontinued before 24wk. due to AES
  • The interim results in the (Forte) trial for beta-thalassemia demonstrated no benefit in transfusion burden or improvement in disease-related biomarkers while 1 NTDT & 8 TDT patients (3.3% and 10.8%) discontinued the study due to AEs. The therapy was well-tolerated across both studies

Ref: Globe Newswire | Image: Businesswire

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions